Archives — October 2016 back to current month (3)
Exploring Solutions to Healthcare's Spending Crisis (10/19/2016)
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures.
Analysts Keep Focus on DURECT's DUR-928 (10/06/2016)
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma.
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.
|"Q3/17 was, by far, VIVE's strongest, with 47 U.S. console placements."|
|"We are initiating coverage on RVX with a Buy rating."|
|"RXII's sd-rxRNA can augment already amazing results in immunotherapy."|